| Finkelstein Thompson LLP Announces Investigation of VNUS Medical Technologies |
|
|
|
| Written by Globe NewsWire | |
| Wednesday, 20 May 2009 | |
|
Washington, DC - Finkelstein Thompson LLP is investigating potential shareholder claims arising from the proposed acquisition of VNUS Medical Technologies ("VNUS" or the "Company") (Nasdaq:VNUS) by Covidien, Ltd. ("Covidien"). Under the terms of the merger agreement, VNUS shareholders will receive $29 per share in cash.
The investigation is focused on the potential unfairness of the merger price and of the process by which the VNUS Board of Directors approved the agreement. If you are interested in discussing your rights as a VNUS shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at This e-mail address is being protected from spam bots, you need JavaScript enabled to view it Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com. |
| < Prev | Next > |
|---|
